MedTrace Logo

Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

NCT07770100 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2026-08-20

No results posted yet for this study

Summary

This is a Phase II clinical study for people with stage IV cancer. The study will evaluate the use of stereotactic body radiation therapy (SBRT), a type of focused radiation treatment, together with immunotherapy-based treatment. SRBT will be used to treat multiple areas of cancer that have spread to other parts of the body. The study will evaluate whether this treatment approach can be safely given while patients continue their planned cancer treatment and may help control their cancer.

Conditions

Interventions

RADIATION

Stereotactic Body Radiation Therapy (SBRT)

SBRT administered to 6-10 metastatic lesions during the first cycle of immunotherapy.

DRUG

Pembrolizumab

FDA-approved immune checkpoint inhibitor administered according to standard clinical practice and disease-specific indications.

DRUG

Nivolumab

FDA-approved immune checkpoint inhibitor administered according to standard clinical practice and disease-specific indications.

DRUG

Atezolizumab

FDA-approved immune checkpoint inhibitor administered according to clinical practice and disease-specific indications.

DRUG

Ipilimumab

FDA-approved immune checkpoint inhibitor administered according to standard clinical practice and disease-specific indications.

Sponsors & Collaborators

  • Mark Bernard

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2040-02-28
Completion
2040-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07770100 on ClinicalTrials.gov